TELOS Trademark

Trademark Overview

On Friday, October 14, 2022, a trademark application was filed for TELOS with the United States Patent and Trademark Office. The USPTO has given the TELOS trademark a serial number of 97632106. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Thursday, March 13, 2025. This trademark is owned by Cambrian BioPharma, Inc.. The TELOS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Drug discovery services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research and development; Research and development of technology in the field of human longevity; Research and development of technology in the field of extending the human lifespan; Scientific research for medical purposes in the field of human longevity; Scientific research for medical purposes in the field of extending the human lifespan
telos

General Information

Serial Number97632106
Word MarkTELOS
Filing DateFriday, October 14, 2022
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateThursday, March 13, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 7, 2024

Trademark Statements

Goods and ServicesDrug discovery services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research and development; Research and development of technology in the field of human longevity; Research and development of technology in the field of extending the human lifespan; Scientific research for medical purposes in the field of human longevity; Scientific research for medical purposes in the field of extending the human lifespan

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, October 28, 2022
Primary Code042
First Use Anywhere DateTuesday, June 27, 2023
First Use In Commerce DateTuesday, June 27, 2023

Trademark Owner History

Party NameCambrian BioPharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10003
Party NameCambrian BioPharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10003

Trademark Events

Event DateEvent Description
Tuesday, October 18, 2022NEW APPLICATION ENTERED
Friday, October 28, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, July 7, 2023ASSIGNED TO EXAMINER
Monday, July 10, 2023NON-FINAL ACTION WRITTEN
Monday, July 10, 2023NON-FINAL ACTION E-MAILED
Monday, July 10, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, October 5, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 5, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 5, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 29, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, November 29, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, November 29, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, December 5, 2023NON-FINAL ACTION WRITTEN
Tuesday, December 5, 2023NON-FINAL ACTION E-MAILED
Tuesday, December 5, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, February 27, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 27, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 27, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, April 1, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 17, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 7, 2024PUBLISHED FOR OPPOSITION
Tuesday, May 7, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 2, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Saturday, December 28, 2024USE AMENDMENT FILED
Saturday, December 28, 2024TEAS STATEMENT OF USE RECEIVED
Friday, March 7, 2025STATEMENT OF USE PROCESSING COMPLETE
Friday, March 7, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, March 13, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, March 13, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

Related Keywords

telos development research human field pharmaceutical longevity extending scientific purposes medical